Welcome to our dedicated page for Penumbra news (Ticker: PEN), a resource for investors and traders seeking the latest updates and insights on Penumbra stock.
Penumbra, Inc. develops thrombectomy technologies for medical conditions involving blood clots, including ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Its product portfolio includes computer assisted vacuum thrombectomy and devices such as the Indigo System, Penumbra System Reperfusion Catheter, ACE Reperfusion Catheters, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and Artemis Neuro Evacuation Device.
Recurring company news covers financial results, capital-structure updates, investor conference presentations, and clinical evidence for CAVT in pulmonary embolism and other vascular applications. Updates also include material agreements, shareholder voting matters, governance disclosures, and regulatory or clinical developments tied to Penumbra's thrombectomy and neurovascular products.
Penumbra, Inc. (NYSE: PEN) reported a 21.7% decline in revenues to $105.1 million for Q2 2020 compared to Q2 2019. US revenue reached $78.0 million, down approximately 10% year-over-year. The company's gross profit was $64.9 million, reflecting a margin decrease to 61.8%. Total operating expenses rose to $82.6 million, leading to an operating loss of $17.6 million. The COVID-19 pandemic continues to impact business operations, and the company cannot reliably estimate future effects.
Penumbra, Inc. (NYSE: PEN) will present at the Canaccord Genuity 40th Annual Growth Conference on August 12, 2020, at 3:30 PM EDT. The presentation will be available via webcast through the company’s investor section on its website, accessible for two weeks post-event. Based in Alameda, California, Penumbra focuses on innovative therapies across healthcare, targeting significant medical needs and selling products mainly in the U.S., Europe, Canada, and Australia.
Penumbra, Inc. (NYSE: PEN) has announced a conference call scheduled for August 3, 2020, at 4:30 PM ET to discuss its financial results for the second quarter of 2020. A press release detailing the financial results will be issued after market close on the same day. The conference call can be accessed by phone or via webcast on the company’s website. Penumbra is a global healthcare company focused on innovative therapies and sells its products to hospitals and healthcare providers primarily through a direct sales organization.